Global Microbiome Drugs Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028

Global Microbiome Drugs Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028

Table of Contents
1 Study Coverage
1.1 Microbiome Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Microbiome Drugs Market Size Growth Rate by Type (2017 VS 2021 VS 2028)
1.2.2 Oral Dosage Form
1.2.3 Enteric Capsules
1.3 Market by Symptom
1.3.1 Global Microbiome Drugs Market Size Growth Rate by Symptom (2017 VS 2021 VS 2028)
1.3.2 Gastrointestinal Disorders
1.3.3 Autoimmune Disorders
1.3.4 Diabetes
1.3.5 Cancer
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Microbiome Drugs Market Size Estimates and Forecasts
2.2 Microbiome Drugs Market Size by Region: 2022 Versus 2028
2.2.1 Global Microbiome Drugs Revenue by Region: 2017-2022
2.2.2 Global Microbiome Drugs Revenue Forecast by Region (2023-2028)
2.2.3 Global Microbiome Drugs Revenue Market Share by Region (2017-2028)
3 Global Microbiome Drugs by Company
3.1 Global Microbiome Drugs Revenue by Company (2017-2022)
3.2 Global Microbiome Drugs Revenue Share by Company (2017-2022)
3.3 Competitive Landscape
3.3.1 Key Microbiome Drugs Companies around the World: Ranking by Revenue
3.3.2 Global Microbiome Drugs Market Concentration Ratio (CR5 and HHI) & (2017-2022)
3.3.3 Global Microbiome Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.4 Global Microbiome Drugs Companies Headquarters & Product Type
3.4.1 Microbiome Drugs Companies Headquarters
3.4.2 Global Microbiome Drugs Companies Product & Service
3.4.3 Date of International Companies Enter into Microbiome Drugs Market
3.5 Global Microbiome Drugs Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Seres Therapeutics
4.1.1 Seres Therapeutics Corporation Information
4.1.2 Seres Therapeutics Description, Business Overview
4.1.3 Seres Therapeutics Microbiome Drugs Products Offered
4.1.4 Seres Therapeutics Microbiome Drugs Revenue and Gross Margin (2017-2022)
4.1.5 Seres Therapeutics Microbiome Drugs Revenue by Product in 2021
4.1.6 Seres Therapeutics Microbiome Drugs Revenue by Symptom in 2021
4.1.7 Seres Therapeutics Microbiome Drugs Revenue by Geographic Area in 2021
4.1.8 Seres Therapeutics Recent Developments
4.2 Assembly Biosciences
4.2.1 Assembly Biosciences Corporation Information
4.2.2 Assembly Biosciences Description, Business Overview
4.2.3 Assembly Biosciences Microbiome Drugs Products Offered
4.2.4 Assembly Biosciences Microbiome Drugs Revenue and Gross Margin (2017-2022)
4.2.5 Assembly Biosciences Microbiome Drugs Revenue by Product in 2021
4.2.6 Assembly Biosciences Microbiome Drugs Revenue by Symptom in 2021
4.2.7 Assembly Biosciences Microbiome Drugs Revenue by Geographic Area in 2021
4.2.8 Assembly Biosciences Recent Developments
4.3 Synthetic Biologics
4.3.1 Synthetic Biologics Corporation Information
4.3.2 Synthetic Biologics Description, Business Overview
4.3.3 Synthetic Biologics Microbiome Drugs Products Offered
4.3.4 Synthetic Biologics Microbiome Drugs Revenue and Gross Margin (2017-2022)
4.3.5 Synthetic Biologics Microbiome Drugs Revenue by Product in 2021
4.3.6 Synthetic Biologics Microbiome Drugs Revenue by Symptom in 2021
4.3.7 Synthetic Biologics Microbiome Drugs Revenue by Geographic Area in 2021
4.3.8 Synthetic Biologics Recent Developments
4.4 Interxon
4.4.1 Interxon Corporation Information
4.4.2 Interxon Description, Business Overview
4.4.3 Interxon Microbiome Drugs Products Offered
4.4.4 Interxon Microbiome Drugs Revenue and Gross Margin (2017-2022)
4.4.5 Interxon Microbiome Drugs Revenue by Product in 2021
4.4.6 Interxon Microbiome Drugs Revenue by Symptom in 2021
4.4.7 Interxon Microbiome Drugs Revenue by Geographic Area in 2021
4.4.8 Interxon Recent Developments
4.5 PureTech
4.5.1 PureTech Corporation Information
4.5.2 PureTech Description, Business Overview
4.5.3 PureTech Microbiome Drugs Products Offered
4.5.4 PureTech Microbiome Drugs Revenue and Gross Margin (2017-2022)
4.5.5 PureTech Microbiome Drugs Revenue by Product in 2021
4.5.6 PureTech Microbiome Drugs Revenue by Symptom in 2021
4.5.7 PureTech Microbiome Drugs Revenue by Geographic Area in 2021
4.5.8 PureTech Recent Developments
4.6 Synlogic
4.6.1 Synlogic Corporation Information
4.6.2 Synlogic Description, Business Overview
4.6.3 Synlogic Microbiome Drugs Products Offered
4.6.4 Synlogic Microbiome Drugs Revenue and Gross Margin (2017-2022)
4.6.5 Synlogic Microbiome Drugs Revenue by Product in 2021
4.6.6 Synlogic Microbiome Drugs Revenue by Symptom in 2021
4.6.7 Synlogic Microbiome Drugs Revenue by Geographic Area in 2021
4.6.8 Synlogic Recent Development
4.7 Enterome BioScience
4.7.1 Enterome BioScience Corporation Information
4.7.2 Enterome BioScience Description, Business Overview
4.7.3 Enterome BioScience Microbiome Drugs Products Offered
4.7.4 Enterome BioScience Microbiome Drugs Revenue and Gross Margin (2017-2022)
4.7.5 Enterome BioScience Microbiome Drugs Revenue by Product in 2021
4.7.6 Enterome BioScience Microbiome Drugs Revenue by Symptom in 2021
4.7.7 Enterome BioScience Microbiome Drugs Revenue by Geographic Area in 2021
4.7.8 Enterome BioScience Recent Development
4.8 4D Pharma
4.8.1 4D Pharma Corporation Information
4.8.2 4D Pharma Description, Business Overview
4.8.3 4D Pharma Microbiome Drugs Products Offered
4.8.4 4D Pharma Microbiome Drugs Revenue and Gross Margin (2017-2022)
4.8.5 4D Pharma Microbiome Drugs Revenue by Product in 2021
4.8.6 4D Pharma Microbiome Drugs Revenue by Symptom in 2021
4.8.7 4D Pharma Microbiome Drugs Revenue by Geographic Area in 2021
4.8.8 4D Pharma Recent Development
4.9 Second Genome
4.9.1 Second Genome Corporation Information
4.9.2 Second Genome Description, Business Overview
4.9.3 Second Genome Microbiome Drugs Products Offered
4.9.4 Second Genome Microbiome Drugs Revenue and Gross Margin (2017-2022)
4.9.5 Second Genome Microbiome Drugs Revenue by Product in 2021
4.9.6 Second Genome Microbiome Drugs Revenue by Symptom in 2021
4.9.7 Second Genome Microbiome Drugs Revenue by Geographic Area in 2021
4.9.8 Second Genome Recent Development
4.10 AOBiome
4.10.1 AOBiome Corporation Information
4.10.2 AOBiome Description, Business Overview
4.10.3 AOBiome Microbiome Drugs Products Offered
4.10.4 AOBiome Microbiome Drugs Revenue and Gross Margin (2017-2022)
4.10.5 AOBiome Microbiome Drugs Revenue by Product in 2021
4.10.6 AOBiome Microbiome Drugs Revenue by Symptom in 2021
4.10.7 AOBiome Microbiome Drugs Revenue by Geographic Area in 2021
4.10.8 AOBiome Recent Development
4.11 Rebiotix
4.11.1 Rebiotix Corporation Information
4.11.2 Rebiotix Description, Business Overview
4.11.3 Rebiotix Microbiome Drugs Products Offered
4.11.4 Rebiotix Microbiome Drugs Revenue and Gross Margin (2017-2022)
4.11.5 Rebiotix Microbiome Drugs Revenue by Product in 2021
4.11.6 Rebiotix Microbiome Drugs Revenue by Symptom in 2021
4.11.7 Rebiotix Microbiome Drugs Revenue by Geographic Area in 2021
4.11.8 Rebiotix Recent Development
4.12 Metabiomics
4.12.1 Metabiomics Corporation Information
4.12.2 Metabiomics Description, Business Overview
4.12.3 Metabiomics Microbiome Drugs Products Offered
4.12.4 Metabiomics Microbiome Drugs Revenue and Gross Margin (2017-2022)
4.12.5 Metabiomics Microbiome Drugs Revenue by Product in 2021
4.12.6 Metabiomics Microbiome Drugs Revenue by Symptom in 2021
4.12.7 Metabiomics Microbiome Drugs Revenue by Geographic Area in 2021
4.12.8 Metabiomics Recent Development
4.13 Ritter Pharmaceuticals
4.13.1 Ritter Pharmaceuticals Corporation Information
4.13.2 Ritter Pharmaceuticals Description, Business Overview
4.13.3 Ritter Pharmaceuticals Microbiome Drugs Products Offered
4.13.4 Ritter Pharmaceuticals Microbiome Drugs Revenue and Gross Margin (2017-2022)
4.13.5 Ritter Pharmaceuticals Microbiome Drugs Revenue by Product in 2021
4.13.6 Ritter Pharmaceuticals Microbiome Drugs Revenue by Symptom in 2021
4.13.7 Ritter Pharmaceuticals Microbiome Drugs Revenue by Geographic Area in 2021
4.13.8 Ritter Pharmaceuticals Recent Development
4.14 Symberix
4.14.1 Symberix Corporation Information
4.14.2 Symberix Description, Business Overview
4.14.3 Symberix Microbiome Drugs Products Offered
4.14.4 Symberix Microbiome Drugs Revenue and Gross Margin (2017-2022)
4.14.5 Symberix Microbiome Drugs Revenue by Product in 2021
4.14.6 Symberix Microbiome Drugs Revenue by Symptom in 2021
4.14.7 Symberix Microbiome Drugs Revenue by Geographic Area in 2021
4.14.8 Symberix Recent Development
4.15 OpenBiome
4.15.1 OpenBiome Corporation Information
4.15.2 OpenBiome Description, Business Overview
4.15.3 OpenBiome Microbiome Drugs Products Offered
4.15.4 OpenBiome Microbiome Drugs Revenue and Gross Margin (2017-2022)
4.15.5 OpenBiome Microbiome Drugs Revenue by Product in 2021
4.15.6 OpenBiome Microbiome Drugs Revenue by Symptom in 2021
4.15.7 OpenBiome Microbiome Drugs Revenue by Geographic Area in 2021
4.15.8 OpenBiome Recent Development
4.16 Azitra
4.16.1 Azitra Corporation Information
4.16.2 Azitra Description, Business Overview
4.16.3 Azitra Microbiome Drugs Products Offered
4.16.4 Azitra Microbiome Drugs Revenue and Gross Margin (2017-2022)
4.16.5 Azitra Microbiome Drugs Revenue by Product in 2021
4.16.6 Azitra Microbiome Drugs Revenue by Symptom in 2021
4.16.7 Azitra Microbiome Drugs Revenue by Geographic Area in 2021
4.16.8 Azitra Recent Development
4.17 Osel
4.17.1 Osel Corporation Information
4.17.2 Osel Description, Business Overview
4.17.3 Osel Microbiome Drugs Products Offered
4.17.4 Osel Microbiome Drugs Revenue and Gross Margin (2017-2022)
4.17.5 Osel Microbiome Drugs Revenue by Product in 2021
4.17.6 Osel Microbiome Drugs Revenue by Symptom in 2021
4.17.7 Osel Microbiome Drugs Revenue by Geographic Area in 2021
4.17.8 Osel Recent Development
5 Breakdown Data by Type
5.1 Global Microbiome Drugs Revenue by Type (2017-2022)
5.2 Global Microbiome Drugs Revenue Forecast by Type (2023-2028)
5.3 Microbiome Drugs Revenue Marke Share by Type (2017-2028)
6 Breakdown Data by Symptom
6.1 Global Microbiome Drugs Revenue by Symptom (2017-2022)
6.2 Global Microbiome Drugs Revenue Forecast by Symptom (2023-2028)
6.3 Microbiome Drugs Revenue Market Share by Symptom (2017-2028)
7 North America
7.1 North America Microbiome Drugs Market Size YoY Growth 2017-2028
7.2 North America Microbiome Drugs Market Facts & Figures by Country (2017-2028)
7.3 North America Microbiome Drugs Revenue by Type (2017-2022)
7.4 North America Microbiome Drugs Revenue by Symptom (2017-2022)
8 Asia-Pacific
8.1 Asia-Pacific Microbiome Drugs Market Size YoY Growth 2017-2028
8.2 Asia-Pacific Microbiome Drugs Market Facts & Figures by Region (2017-2028)
8.3 Asia-Pacific Microbiome Drugs Revenue by Type (2017-2022)
8.4 Asia-Pacific Microbiome Drugs Revenue by Symptom (2017-2022)
9 Europe
9.1 Europe Microbiome Drugs Market Size YoY Growth 2017-2028
9.2 Europe Microbiome Drugs Market Facts & Figures by Country (2017-2028)
9.3 Europe Microbiome Drugs Revenue by Type (2017-2022)
9.4 Europe Microbiome Drugs Revenue by Symptom (2017-2022)
10 Latin America
10.1 Latin America Microbiome Drugs Market Size YoY Growth 2017-2028
10.2 Latin America Microbiome Drugs Market Facts & Figures by Country (2017-2028)
10.3 Latin America Microbiome Drugs Revenue by Type (2017-2022)
10.4 Latin America Microbiome Drugs Revenue by Symptom (2017-2022)
11 Middle East and Africa
11.1 Middle East and Africa Microbiome Drugs Market Size YoY Growth 2017-2028
11.2 Middle East and Africa Microbiome Drugs Market Facts & Figures by Country (2017-2028)
11.3 Middle East and Africa Microbiome Drugs Revenue by Type (2017-2022)
11.4 Middle East and Africa Microbiome Drugs Revenue by Symptom (2017-2022)
12 Supply Chain and Sales Channel Analysis
12.1 Microbiome Drugs Supply Chain Analysis
12.2 Microbiome Drugs Key Raw Materials and Upstream Suppliers
12.3 Microbiome Drugs Clients Analysis
12.4 Microbiome Drugs Sales Channel and Sales Model Analysis
12.4.1 Microbiome Drugs Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Microbiome Drugs Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Microbiome Drugs Distributors
13 Market Dynamics
13.1 Microbiome Drugs Industry Trends
13.2 Microbiome Drugs Market Drivers
13.3 Microbiome Drugs Market Challenges
13.4 Microbiome Drugs Market Restraints
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Microbiome Drugs Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Major Companies of Oral Dosage Form
Table 3. Major Companies of Enteric Capsules
Table 4. Global Microbiome Drugs Market Size Growth by Symptom (US$ Million): 2017 VS 2021 VS 2028
Table 5. Global Microbiome Drugs Market Size by Region (US$ Million): 2022 VS 2028
Table 6. Global Microbiome Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 7. Global Microbiome Drugs Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 8. Microbiome Drugs Revenue by Company (2017-2022) & (US$ Million)
Table 9. Microbiome Drugs Revenue Share by Company (2017-2022)
Table 10. Ranking of Global Top Microbiome Drugs Players by Revenue (US$ Million) in 2021
Table 11. Global Microbiome Drugs Companies Market Concentration Ratio (CR5 and HHI) & (2017-2022)
Table 12. Global Microbiome Drugs by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Microbiome Drugs as of 2021)
Table 13. Global Microbiome Drugs Companies Headquarters
Table 14. Global Microbiome Drugs Companies Product & Service
Table 15. Date of International Companies Enter into Microbiome Drugs Market
Table 16. Global Microbiome Drugs Mergers & Acquisitions, Expansion Plans
Table 17. Seres Therapeutics Corporation Information
Table 18. Seres Therapeutics Description and Business Overview
Table 19. Seres Therapeutics Microbiome Drugs Revenue (US$ Million) and Gross Margin (2017-2022)
Table 20. Seres Therapeutics Microbiome Drugs Product
Table 21. Seres Therapeutics Microbiome Drugs Revenue Proportion of Microbiome Drugs by Product in 2021
Table 22. Seres Therapeutics Microbiome Drugs Revenue Proportion of Microbiome Drugs by Symptom in 2021
Table 23. Seres Therapeutics Microbiome Drugs Revenue Proportion of Microbiome Drugs by Geographic Area in 2021
Table 24. Seres Therapeutics Recent Development
Table 25. Assembly Biosciences Corporation Information
Table 26. Assembly Biosciences Description and Business Overview
Table 27. Assembly Biosciences Microbiome Drugs Revenue (US$ Million) and Gross Margin (2017-2022)
Table 28. Assembly Biosciences Microbiome Drugs Product
Table 29. Assembly Biosciences Microbiome Drugs Revenue Proportion of Microbiome Drugs by Product in 2021
Table 30. Assembly Biosciences Microbiome Drugs Revenue Proportion of Microbiome Drugs by Symptom in 2021
Table 31. Assembly Biosciences Microbiome Drugs Revenue Proportion of Microbiome Drugs by Geographic Area in 2021
Table 32. Assembly Biosciences Recent Development
Table 33. Synthetic Biologics Corporation Information
Table 34. Synthetic Biologics Description and Business Overview
Table 35. Synthetic Biologics Microbiome Drugs Revenue (US$ Million) and Gross Margin (2017-2022)
Table 36. Synthetic Biologics Microbiome Drugs Product
Table 37. Synthetic Biologics Microbiome Drugs Revenue Proportion of Microbiome Drugs by Product in 2021
Table 38. Synthetic Biologics Microbiome Drugs Revenue Proportion of Microbiome Drugs by Symptom in 2021
Table 39. Synthetic Biologics Microbiome Drugs Revenue Proportion of Microbiome Drugs by Geographic Area in 2021
Table 40. Synthetic Biologics Recent Development
Table 41. Interxon Corporation Information
Table 42. Interxon Description and Business Overview
Table 43. Interxon Microbiome Drugs Revenue (US$ Million) and Gross Margin (2017-2022)
Table 44. Interxon Microbiome Drugs Product
Table 45. Interxon Microbiome Drugs Revenue Proportion of Microbiome Drugs by Product in 2021
Table 46. Interxon Microbiome Drugs Revenue Proportion of Microbiome Drugs by Symptom in 2021
Table 47. Interxon Microbiome Drugs Revenue Proportion of Microbiome Drugs by Geographic Area in 2021
Table 48. Interxon Recent Development
Table 49. PureTech Corporation Information
Table 50. PureTech Description and Business Overview
Table 51. PureTech Microbiome Drugs Revenue (US$ Million) and Gross Margin (2017-2022)
Table 52. PureTech Microbiome Drugs Product
Table 53. PureTech Microbiome Drugs Revenue Proportion of Microbiome Drugs by Product in 2021
Table 54. PureTech Microbiome Drugs Revenue Proportion of Microbiome Drugs by Symptom in 2021
Table 55. PureTech Microbiome Drugs Revenue Proportion of Microbiome Drugs by Geographic Area in 2021
Table 56. PureTech Recent Development
Table 57. Synlogic Corporation Information
Table 58. Synlogic Description and Business Overview
Table 59. Synlogic Microbiome Drugs Revenue (US$ Million) and Gross Margin (2017-2022)
Table 60. Synlogic Microbiome Drugs Product
Table 61. Synlogic Microbiome Drugs Revenue Proportion of Microbiome Drugs by Product in 2021
Table 62. Synlogic Microbiome Drugs Revenue Proportion of Microbiome Drugs by Symptom in 2021
Table 63. Synlogic Microbiome Drugs Revenue Proportion of Microbiome Drugs by Geographic Area in 2021
Table 64. Enterome BioScience Corporation Information
Table 65. Enterome BioScience Description and Business Overview
Table 66. Enterome BioScience Microbiome Drugs Revenue (US$ Million) and Gross Margin (2017-2022)
Table 67. Enterome BioScience Microbiome Drugs Product
Table 68. Enterome BioScience Microbiome Drugs Revenue Proportion of Microbiome Drugs by Product in 2021
Table 69. Enterome BioScience Microbiome Drugs Revenue Proportion of Microbiome Drugs by Symptom in 2021
Table 70. Enterome BioScience Microbiome Drugs Revenue Proportion of Microbiome Drugs by Geographic Area in 2021
Table 71. 4D Pharma Corporation Information
Table 72. 4D Pharma Description and Business Overview
Table 73. 4D Pharma Microbiome Drugs Revenue (US$ Million) and Gross Margin (2017-2022)
Table 74. 4D Pharma Microbiome Drugs Product
Table 75. 4D Pharma Microbiome Drugs Revenue Proportion of Microbiome Drugs by Product in 2021
Table 76. 4D Pharma Microbiome Drugs Revenue Proportion of Microbiome Drugs by Symptom in 2021
Table 77. 4D Pharma Microbiome Drugs Revenue Proportion of Microbiome Drugs by Geographic Area in 2021
Table 78. Second Genome Corporation Information
Table 79. Second Genome Description and Business Overview
Table 80. Second Genome Microbiome Drugs Revenue (US$ Million) and Gross Margin (2017-2022)
Table 81. Second Genome Microbiome Drugs Product
Table 82. Second Genome Microbiome Drugs Revenue Proportion of Microbiome Drugs by Product in 2021
Table 83. Second Genome Microbiome Drugs Revenue Proportion of Microbiome Drugs by Symptom in 2021
Table 84. Second Genome Microbiome Drugs Revenue Proportion of Microbiome Drugs by Geographic Area in 2021
Table 85. AOBiome Corporation Information
Table 86. AOBiome Description and Business Overview
Table 87. AOBiome Microbiome Drugs Revenue (US$ Million) and Gross Margin (2017-2022)
Table 88. AOBiome Microbiome Drugs Product
Table 89. AOBiome Microbiome Drugs Revenue Proportion of Microbiome Drugs by Product in 2021
Table 90. AOBiome Microbiome Drugs Revenue Proportion of Microbiome Drugs by Symptom in 2021
Table 91. AOBiome Microbiome Drugs Revenue Proportion of Microbiome Drugs by Geographic Area in 2021
Table 92. Rebiotix Corporation Information
Table 93. Rebiotix Description and Business Overview
Table 94. Rebiotix Microbiome Drugs Revenue (US$ Million) and Gross Margin (2017-2022)
Table 95. Rebiotix Microbiome Drugs Product
Table 96. Rebiotix Microbiome Drugs Revenue Proportion of Microbiome Drugs by Product in 2021
Table 97. Rebiotix Microbiome Drugs Revenue Proportion of Microbiome Drugs by Symptom in 2021
Table 98. Rebiotix Microbiome Drugs Revenue Proportion of Microbiome Drugs by Geographic Area in 2021
Table 99. Metabiomics Corporation Information
Table 100. Metabiomics Description and Business Overview
Table 101. Metabiomics Microbiome Drugs Revenue (US$ Million) and Gross Margin (2017-2022)
Table 102. Metabiomics Microbiome Drugs Product
Table 103. Metabiomics Microbiome Drugs Revenue Proportion of Microbiome Drugs by Product in 2021
Table 104. Metabiomics Microbiome Drugs Revenue Proportion of Microbiome Drugs by Symptom in 2021
Table 105. Metabiomics Microbiome Drugs Revenue Proportion of Microbiome Drugs by Geographic Area in 2021
Table 106. Ritter Pharmaceuticals Corporation Information
Table 107. Ritter Pharmaceuticals Description and Business Overview
Table 108. Ritter Pharmaceuticals Microbiome Drugs Revenue (US$ Million) and Gross Margin (2017-2022)
Table 109. Ritter Pharmaceuticals Microbiome Drugs Product
Table 110. Ritter Pharmaceuticals Microbiome Drugs Revenue Proportion of Microbiome Drugs by Product in 2021
Table 111. Ritter Pharmaceuticals Microbiome Drugs Revenue Proportion of Microbiome Drugs by Symptom in 2021
Table 112. Ritter Pharmaceuticals Microbiome Drugs Revenue Proportion of Microbiome Drugs by Geographic Area in 2021
Table 113. Symberix Corporation Information
Table 114. Symberix Description and Business Overview
Table 115. Symberix Microbiome Drugs Revenue (US$ Million) and Gross Margin (2017-2022)
Table 116. Symberix Microbiome Drugs Product
Table 117. Symberix Microbiome Drugs Revenue Proportion of Microbiome Drugs by Product in 2021
Table 118. Symberix Microbiome Drugs Revenue Proportion of Microbiome Drugs by Symptom in 2021
Table 119. Symberix Microbiome Drugs Revenue Proportion of Microbiome Drugs by Geographic Area in 2021
Table 120. OpenBiome Corporation Information
Table 121. OpenBiome Description and Business Overview
Table 122. OpenBiome Microbiome Drugs Revenue (US$ Million) and Gross Margin (2017-2022)
Table 123. OpenBiome Microbiome Drugs Product
Table 124. OpenBiome Microbiome Drugs Revenue Proportion of Microbiome Drugs by Product in 2021
Table 125. OpenBiome Microbiome Drugs Revenue Proportion of Microbiome Drugs by Symptom in 2021
Table 126. OpenBiome Microbiome Drugs Revenue Proportion of Microbiome Drugs by Geographic Area in 2021
Table 127. Azitra Corporation Information
Table 128. Azitra Description and Business Overview
Table 129. Azitra Microbiome Drugs Revenue (US$ Million) and Gross Margin (2017-2022)
Table 130. Azitra Microbiome Drugs Product
Table 131. Azitra Microbiome Drugs Revenue Proportion of Microbiome Drugs by Product in 2021
Table 132. Azitra Microbiome Drugs Revenue Proportion of Microbiome Drugs by Symptom in 2021
Table 133. Azitra Microbiome Drugs Revenue Proportion of Microbiome Drugs by Geographic Area in 2021
Table 134. Osel Corporation Information
Table 135. Osel Description and Business Overview
Table 136. Osel Microbiome Drugs Revenue (US$ Million) and Gross Margin (2017-2022)
Table 137. Osel Microbiome Drugs Product
Table 138. Osel Microbiome Drugs Revenue Proportion of Microbiome Drugs by Product in 2021
Table 139. Osel Microbiome Drugs Revenue Proportion of Microbiome Drugs by Symptom in 2021
Table 140. Osel Microbiome Drugs Revenue Proportion of Microbiome Drugs by Geographic Area in 2021
Table 141. Global Microbiome Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 142. Global Microbiome Drugs Revenue by Symptom (2017-2022) & (US$ Million)
Table 143. Global Microbiome Drugs Revenue Forecast by Symptom (2023-2028) & (US$ Million)
Table 144. North America Microbiome Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 145. North America Microbiome Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 146. North America Microbiome Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 147. North America Microbiome Drugs Revenue by Symptom (2017-2022) & (US$ Million)
Table 148. Asia-Pacific Microbiome Drugs Revenue by Region (2017-2028) & (US$ Million)
Table 149. Asia-Pacific Microbiome Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 150. Asia-Pacific Microbiome Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 151. Asia-Pacific Microbiome Drugs Revenue by Symptom (2017-2022) & (US$ Million)
Table 152. Europe Microbiome Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 153. Europe Microbiome Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 154. Europe Microbiome Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 155. Europe Microbiome Drugs Revenue by Symptom (2017-2022) & (US$ Million)
Table 156. Latin America Microbiome Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 157. Latin America Microbiome Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 158. Latin America Microbiome Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 159. Latin America Microbiome Drugs Revenue by Symptom (2017-2022) & (US$ Million)
Table 160. Middle East and Africa Microbiome Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 161. Middle East and Africa Microbiome Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 162. Middle East and Africa Microbiome Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 163. Middle East and Africa Microbiome Drugs Revenue by Symptom (2017-2022) & (US$ Million)
Table 164. Microbiome Drugs Key Raw Materials, Industry Status and Trend
Table 165. Microbiome Drugs Key Raw Materials and Upstream Suppliers
Table 166. Microbiome Drugs Clients Status and Trend
Table 167. Microbiome Drugs Typical Clients
Table 168. Microbiome Drugs Distributors
Table 169. Microbiome Drugs Market Trends
Table 170. Microbiome Drugs Market Drivers
Table 171. Microbiome Drugs Market Challenges
Table 172. Microbiome Drugs Market Restraints
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
List of Figures
Figure 1. Microbiome Drugs Product Picture
Figure 2. Global Microbiome Drugs Revenue Market Share by Type in 2021 & 2028
Figure 3. Oral Dosage Form Product Picture
Figure 4. Enteric Capsules Product Picture
Figure 5. Global Microbiome Drugs Revenue Market Share by Symptom in 2021 & 2028
Figure 6. Gastrointestinal Disorders
Figure 7. Autoimmune Disorders
Figure 8. Diabetes
Figure 9. Cancer
Figure 10. Others
Figure 11. Microbiome Drugs Report Years Considered
Figure 12. Global Microbiome Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Microbiome Drugs Market Size 2017-2028 (US$ Million)
Figure 14. Global Microbiome Drugs Market Size Market Share by Region: 2022 Versus 2028
Figure 15. Global Microbiome Drugs Revenue Market Share by Region (2017-2028)
Figure 16. Microbiome Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 17. Global Microbiome Drugs Revenue Market Share Forecast by Type (2017-2028)
Figure 18. Global Microbiome Drugs Revenue Market Share Forecast by Symptom (2017-2028)
Figure 19. North America Microbiome Drugs Revenue 2017-2028 (US$ Million)
Figure 20. North America Microbiome Drugs Revenue Market Share by Type (2017-2022)
Figure 21. North America Microbiome Drugs Revenue Market Share by Symptom (2017-2022)
Figure 22. Asia-Pacific Microbiome Drugs Revenue 2017-2028 (US$ Million)
Figure 23. Asia-Pacific Microbiome Drugs Revenue Market Share by Region (2017-2028)
Figure 24. Asia-Pacific Microbiome Drugs Revenue Market Share by Type (2017-2022)
Figure 25. Asia-Pacific Microbiome Drugs Revenue Market Share by Symptom (2017-2022)
Figure 26. Europe Microbiome Drugs Revenue Growth Rate 2017-2028 (US$ Million)
Figure 27. Europe Microbiome Drugs Revenue Market Share by Country (2017-2028)
Figure 28. Europe Microbiome Drugs Revenue Market Share by Type (2017-2022)
Figure 29. Europe Microbiome Drugs Revenue Market Share by Symptom (2017-2022)
Figure 30. Latin America Microbiome Drugs Revenue Growth Rate 2017-2028 (US$ Million)
Figure 31. Latin America Microbiome Drugs Revenue Market Share by Country (2017-2022)
Figure 32. Latin America Microbiome Drugs Revenue Market Share by Type (2017-2022)
Figure 33. Latin America Microbiome Drugs Revenue Market Share by Symptom (2017-2022)
Figure 34. Middle East and Africa Microbiome Drugs Revenue Growth Rate 2017-2028 (US$ Million)
Figure 35. Middle East and Africa Microbiome Drugs Revenue Market Share by Country (2017-2028)
Figure 36. Middle East and Africa Microbiome Drugs Revenue Market Share by Type (2017-2022)
Figure 37. Middle East and Africa Microbiome Drugs Revenue Market Share by Symptom (2017-2022)
Figure 38. Microbiome Drugs Supply Chain (Upstream and Downstream Market)
Figure 39. Global Production Market Share of Microbiome Drugs Raw Materials by Region in 2021
Figure 40. Microbiome Drugs Distribution Channels
Figure 41. Global Microbiome Drugs Percentage 2017-2028: Indirect Sales VS Direct Sales
Figure 42. Global Microbiome Drugs Percentage 2017-2028: Online Sales VS Offline Sales
Figure 43. Bottom-up and Top-down Approaches for This Report
Figure 44. Data Triangulation
Figure 45. Key Executives Interviewed

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Antioxidant Vitamins Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100

The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......

Global Clavulanate Potassium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......

Global Amoxicillin Sodium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84

The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......

Global Melatonin Supplements Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......

Global Sleeping Pills (Prescription Drugs) Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93

The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......

Global Sleeping Pills Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Zinc Oral Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......

Global Zinc Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Anti-Infectives Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs